APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-Drug Conjugate Analysis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibody-Drug Conjugate Analysis Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchAntibody-Drug Conjugate Analysis Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-Drug Conjugate Analysis Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Antibody-Drug Conjugate Analysis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-Drug Conjugate Analysis Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Antibody-Drug Conjugate Analysis Market Analysis and Forecast 2026-2032187 pages · $4,950 USD

Market perspective

The global Antibody-Drug Conjugate Analysis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibody-Drug Conjugate Analysis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody-Drug Conjugate Analysis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody-Drug Conjugate Analysis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibody-Drug Conjugate Analysis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibody-Drug Conjugate Analysis market include SGS SA, Sciex, Bioinformatics Solutions Inc., Intertek, Agilent, Biofidus AG and Creative Biolabs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antibody-Drug Conjugate Analysis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-Drug Conjugate Analysis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-Drug Conjugate Analysis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antibody-Drug Conjugate Analysis market.

Antibody-Drug Conjugate Analysis Segment by Company

SGS SA

Sciex

Bioinformatics Solutions Inc.

Intertek

Agilent

Biofidus AG

Creative Biolabs

Antibody-Drug Conjugate Analysis Segment by Type

Qualitative Analysis

Quantitative Analysis

Antibody-Drug Conjugate Analysis Segment by Application

Pharmaceuticals

Scientific Research

Other

Antibody-Drug Conjugate Analysis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibody-Drug Conjugate Analysis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antibody-Drug Conjugate Analysis key companies, revenue, market share, and recent developments.

3. To split the Antibody-Drug Conjugate Analysis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antibody-Drug Conjugate Analysis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody-Drug Conjugate Analysis significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody-Drug Conjugate Analysis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-Drug Conjugate Analysis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-Drug Conjugate Analysis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-Drug Conjugate Analysis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody-Drug Conjugate Analysis industry.

Chapter 3: Detailed analysis of Antibody-Drug Conjugate Analysis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antibody-Drug Conjugate Analysis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antibody-Drug Conjugate Analysis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody-Drug Conjugate Analysis Industry Trends Table 2. Antibody-Drug Conjugate Analysis Industry Drivers Table 3. Antibody-Drug Conjugate Analysis Industry Opportunities and Challenges Table 4. Antibody-Drug Conjugate Analysis Industry Restraints Table 5. Global Antibody-Drug Conjugate Analysis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody-Drug Conjugate Analysis Revenue Share by Company (2021-2026) Table 7. Global Antibody-Drug Conjugate Analysis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antibody-Drug Conjugate Analysis Key Company Manufacturing Base & Headquarters Table 9. Global Antibody-Drug Conjugate Analysis Company, Product Type & Application Table 10. Global Antibody-Drug Conjugate Analysis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antibody-Drug Conjugate Analysis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Qualitative Analysis Table 15. Significant Companies of Quantitative Analysis Table 16. Global Antibody-Drug Conjugate Analysis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Antibody-Drug Conjugate Analysis Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Antibody-Drug Conjugate Analysis Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Antibody-Drug Conjugate Analysis Sales Value Share by Type (2021-2026) Table 20. Global Antibody-Drug Conjugate Analysis Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceuticals Table 22. Significant Companies of Scientific Research Table 23. Significant Companies of Other Table 24. Global Antibody-Drug Conjugate Analysis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antibody-Drug Conjugate Analysis Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Antibody-Drug Conjugate Analysis Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Antibody-Drug Conjugate Analysis Sales Value Share by Application (2021-2026) Table 28. Global Antibody-Drug Conjugate Analysis Sales Value Share by Application (2027-2032) Table 29. Global Antibody-Drug Conjugate Analysis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Antibody-Drug Conjugate Analysis Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Antibody-Drug Conjugate Analysis Sales Value Share by Region (2021-2026) Table 32. Global Antibody-Drug Conjugate Analysis Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Antibody-Drug Conjugate Analysis Sales Value Share by Region (2027-2032) Table 34. Global Antibody-Drug Conjugate Analysis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Antibody-Drug Conjugate Analysis Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Antibody-Drug Conjugate Analysis Sales Value Market Share by Country (2021-2026) Table 37. Global Antibody-Drug Conjugate Analysis Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Antibody-Drug Conjugate Analysis Sales Value Market Share by Country (2027-2032) Table 39. SGS SA Company Information Table 40. SGS SA Business Overview Table 41. SGS SA Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. SGS SA Antibody-Drug Conjugate Analysis Product Portfolio Table 43. SGS SA Recent Development Table 44. Sciex Company Information Table 45. Sciex Business Overview Table 46. Sciex Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sciex Antibody-Drug Conjugate Analysis Product Portfolio Table 48. Sciex Recent Development Table 49. Bioinformatics Solutions Inc. Company Information Table 50. Bioinformatics Solutions Inc. Business Overview Table 51. Bioinformatics Solutions Inc. Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bioinformatics Solutions Inc. Antibody-Drug Conjugate Analysis Product Portfolio Table 53. Bioinformatics Solutions Inc. Recent Development Table 54. Intertek Company Information Table 55. Intertek Business Overview Table 56. Intertek Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Intertek Antibody-Drug Conjugate Analysis Product Portfolio Table 58. Intertek Recent Development Table 59. Agilent Company Information Table 60. Agilent Business Overview Table 61. Agilent Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Agilent Antibody-Drug Conjugate Analysis Product Portfolio Table 63. Agilent Recent Development Table 64. Biofidus AG Company Information Table 65. Biofidus AG Business Overview Table 66. Biofidus AG Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Biofidus AG Antibody-Drug Conjugate Analysis Product Portfolio Table 68. Biofidus AG Recent Development Table 69. Creative Biolabs Company Information Table 70. Creative Biolabs Business Overview Table 71. Creative Biolabs Antibody-Drug Conjugate Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Creative Biolabs Antibody-Drug Conjugate Analysis Product Portfolio Table 73. Creative Biolabs Recent Development Table 74. Research Programs/Design for This Report Table 75. Authors List of This Report Table 76. Secondary Sources Table 77. Primary Sources List of Figures Figure 1. Antibody-Drug Conjugate Analysis Product Image Figure 2. Global Antibody-Drug Conjugate Analysis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-Drug Conjugate Analysis Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody-Drug Conjugate Analysis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Qualitative Analysis Image Figure 8. Quantitative Analysis Image Figure 9. Global Antibody-Drug Conjugate Analysis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antibody-Drug Conjugate Analysis Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Antibody-Drug Conjugate Analysis Sales Value Share by Type (2021-2032) Figure 12. Pharmaceuticals Image Figure 13. Scientific Research Image Figure 14. Other Image Figure 15. Global Antibody-Drug Conjugate Analysis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antibody-Drug Conjugate Analysis Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antibody-Drug Conjugate Analysis Sales Value Share by Application (2021-2032) Figure 18. Global Antibody-Drug Conjugate Analysis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Antibody-Drug Conjugate Analysis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Antibody-Drug Conjugate Analysis Sales Value (2021-2032) & (US$ Million) Figure 21. North America Antibody-Drug Conjugate Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Antibody-Drug Conjugate Analysis Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Antibody-Drug Conjugate Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Antibody-Drug Conjugate Analysis Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Antibody-Drug Conjugate Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Antibody-Drug Conjugate Analysis Sales Value (2021-2032) & (US$ Million) Figure 27. South America Antibody-Drug Conjugate Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Antibody-Drug Conjugate Analysis Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Antibody-Drug Conjugate Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Qualitative Analysis
  • Quantitative Analysis
Applications
  • Pharmaceuticals
  • Scientific Research
  • Other
Companies covered
  • SGS SA
  • Sciex
  • Bioinformatics Solutions Inc.
  • Intertek
  • Agilent
  • Biofidus AG
  • Creative Biolabs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody-Drug Conjugate Analysis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody-Drug Conjugate Analysis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antibody-Drug Conjugate Analysis Market Dynamics
  1. 2.1 Antibody-Drug Conjugate Analysis Industry Trends
  2. 2.2 Antibody-Drug Conjugate Analysis Industry Drivers
  3. 2.3 Antibody-Drug Conjugate Analysis Industry Opportunities and Challenges
  4. 2.4 Antibody-Drug Conjugate Analysis Industry Restraints
3 Antibody-Drug Conjugate Analysis Market by Company
  1. 3.1 Global Antibody-Drug Conjugate Analysis Company Revenue Ranking in 2025
  2. 3.2 Global Antibody-Drug Conjugate Analysis Revenue by Company (2021-2026)
  3. 3.3 Global Antibody-Drug Conjugate Analysis Company Ranking (2024-2026)
  4. 3.4 Global Antibody-Drug Conjugate Analysis Company Manufacturing Base and Headquarters
  5. 3.5 Global Antibody-Drug Conjugate Analysis Company Product Type and Application
  6. 3.6 Global Antibody-Drug Conjugate Analysis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antibody-Drug Conjugate Analysis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antibody-Drug Conjugate Analysis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antibody-Drug Conjugate Analysis Market by Type
  1. 4.1 Antibody-Drug Conjugate Analysis Type Introduction
  2. 4.1.1 Qualitative Analysis
  3. 4.1.2 Quantitative Analysis
  4. 4.2 Global Antibody-Drug Conjugate Analysis Sales Value by Type
  5. 4.2.1 Global Antibody-Drug Conjugate Analysis Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antibody-Drug Conjugate Analysis Sales Value by Type (2021-2032)
  7. 4.2.3 Global Antibody-Drug Conjugate Analysis Sales Value Share by Type (2021-2032)
5 Antibody-Drug Conjugate Analysis Market by Application
  1. 5.1 Antibody-Drug Conjugate Analysis Application Introduction
  2. 5.1.1 Pharmaceuticals
  3. 5.1.2 Scientific Research
  4. 5.1.3 Other
  5. 5.2 Global Antibody-Drug Conjugate Analysis Sales Value by Application
  6. 5.2.1 Global Antibody-Drug Conjugate Analysis Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibody-Drug Conjugate Analysis Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antibody-Drug Conjugate Analysis Sales Value Share by Application (2021-2032)
6 Antibody-Drug Conjugate Analysis Regional Value Analysis
  1. 6.1 Global Antibody-Drug Conjugate Analysis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody-Drug Conjugate Analysis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antibody-Drug Conjugate Analysis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antibody-Drug Conjugate Analysis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody-Drug Conjugate Analysis Sales Value (2021-2032)
  7. 6.3.2 North America Antibody-Drug Conjugate Analysis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antibody-Drug Conjugate Analysis Sales Value (2021-2032)
  10. 6.4.2 Europe Antibody-Drug Conjugate Analysis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antibody-Drug Conjugate Analysis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antibody-Drug Conjugate Analysis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antibody-Drug Conjugate Analysis Sales Value (2021-2032)
  16. 6.6.2 South America Antibody-Drug Conjugate Analysis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antibody-Drug Conjugate Analysis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antibody-Drug Conjugate Analysis Sales Value Share by Country, 2025 VS 2032
7 Antibody-Drug Conjugate Analysis Country-level Value Analysis
  1. 7.1 Global Antibody-Drug Conjugate Analysis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody-Drug Conjugate Analysis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antibody-Drug Conjugate Analysis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antibody-Drug Conjugate Analysis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antibody-Drug Conjugate Analysis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antibody-Drug Conjugate Analysis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antibody-Drug Conjugate Analysis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 SGS SA
  2. 8.1.1 SGS SA Company Information
  3. 8.1.2 SGS SA Business Overview
  4. 8.1.3 SGS SA Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 SGS SA Antibody-Drug Conjugate Analysis Product Portfolio
  6. 8.1.5 SGS SA Recent Developments
  7. 8.2 Sciex
  8. 8.2.1 Sciex Company Information
  9. 8.2.2 Sciex Business Overview
  10. 8.2.3 Sciex Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sciex Antibody-Drug Conjugate Analysis Product Portfolio
  12. 8.2.5 Sciex Recent Developments
  13. 8.3 Bioinformatics Solutions Inc.
  14. 8.3.1 Bioinformatics Solutions Inc. Company Information
  15. 8.3.2 Bioinformatics Solutions Inc. Business Overview
  16. 8.3.3 Bioinformatics Solutions Inc. Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bioinformatics Solutions Inc. Antibody-Drug Conjugate Analysis Product Portfolio
  18. 8.3.5 Bioinformatics Solutions Inc. Recent Developments
  19. 8.4 Intertek
  20. 8.4.1 Intertek Company Information
  21. 8.4.2 Intertek Business Overview
  22. 8.4.3 Intertek Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Intertek Antibody-Drug Conjugate Analysis Product Portfolio
  24. 8.4.5 Intertek Recent Developments
  25. 8.5 Agilent
  26. 8.5.1 Agilent Company Information
  27. 8.5.2 Agilent Business Overview
  28. 8.5.3 Agilent Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Agilent Antibody-Drug Conjugate Analysis Product Portfolio
  30. 8.5.5 Agilent Recent Developments
  31. 8.6 Biofidus AG
  32. 8.6.1 Biofidus AG Company Information
  33. 8.6.2 Biofidus AG Business Overview
  34. 8.6.3 Biofidus AG Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biofidus AG Antibody-Drug Conjugate Analysis Product Portfolio
  36. 8.6.5 Biofidus AG Recent Developments
  37. 8.7 Creative Biolabs
  38. 8.7.1 Creative Biolabs Company Information
  39. 8.7.2 Creative Biolabs Business Overview
  40. 8.7.3 Creative Biolabs Antibody-Drug Conjugate Analysis Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Creative Biolabs Antibody-Drug Conjugate Analysis Product Portfolio
  42. 8.7.5 Creative Biolabs Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst